The global antifibrotic drugs market is anticipated to grow at a significant CAGR during the forecast period. The key factor that is anticipated to drive the market growth includes the rising prevalence of idiopathic pulmonary fibrosis and the growing R&D activities. Idiopathic pulmonary fibrosis is a serious, though rare disease majorly affecting human lungs. It primarily leads to the building up of scar tissue within the lungs. This stiffens them as such where they fail to contract and expand. Talking about idiopathic pulmonary fibrosis, in the US alone about 30,000 to 40,000 new cases are found each year, as per the National Institutes of Health (NIH). Across the globe, the incidence of idiopathic pulmonary fibrosis is estimated to be 10.7 cases per 100,000 person-years for males and 7.4 cases per 100,000 person-years for females. The prevalence of idiopathic pulmonary fibrosis is estimated to be 20 cases per 100,000 persons for males and 13 cases per 100,000 persons for females.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/antifibrotic-drugs-market
Some key players operating in the market include Boehringer Ingelheim GmbH, F. Hoffman La-Roche AG, and Bristol-Myers Squibb Company, among others. Further, Esbriet, an oral pirfenidone approved for the treatment of idiopathic pulmonary fibrosis and is available in around 40 countries globally received the Orphan Drug Designation and was approved for use in Europe in 2011 in adults with mild-to-moderate idiopathic pulmonary fibrosis (and in the US in people with idiopathic pulmonary fibrosis in October 2014).
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered
- Regions Covered- Globally
Competitive Landscape: Boehringer Ingelheim GmbH, F. Hoffman La-Roche AG, and Bristol-Myers Squibb Company, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Antifibrotic Drugs Market by Segmentation
By Type
- Oral
- Injectable
- Topical
By Application
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
A full report of Antifibrotic Drugs Market is available at: https://www.omrglobal.com/industry-reports/antifibrotic-drugs-market
Antifibrotic Drugs Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Boehringer Ingelheim GmbH
- Hoffman La-Roche AG
- Bristol-Myers Squibb Company
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
